cyc 202 has been researched along with Experimental Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, C; Ullah, S; Yuan, Q; Yun, F | 1 |
| Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P | 1 |
| Chiocca, EA; Deckter, LA; Kasai, K; Saeki, Y; Yamamoto, S | 1 |
3 other study(ies) available for cyc 202 and Experimental Neoplasms
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Female; Histone Deacetylases; Humans; Male; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Neoplasms, Experimental; Protein Kinase Inhibitors; Purines; Structure-Activity Relationship | 2020 |
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Topics: Animals; Area Under Curve; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Enzyme Inhibitors; Female; HCT116 Cells; Humans; Inhibitory Concentration 50; Kinetin; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Purines; Recombinant Proteins; Retinoblastoma Protein; Roscovitine; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays | 2005 |
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Gene Expression; Genetic Engineering; Genetic Therapy; Genetic Vectors; Herpes Simplex; Herpesvirus 1, Human; Humans; Luciferases; Luminescent Proteins; Mice; Mice, Nude; Models, Animal; Neoplasms, Experimental; Neuroglia; Oncolytic Virotherapy; Phosphonoacetic Acid; Promoter Regions, Genetic; Purines; Roscovitine; Vero Cells; Virus Replication | 2006 |